Axsome Therapeutics (AXSM) Accumulated Expenses (2015 - 2026)

Axsome Therapeutics has reported Accumulated Expenses for 12 years, with the latest figure at $27.0 million in Q1 2026.

• Quarterly Accumulated Expenses rose 37.89% year-over-year to $27.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.0 million (up 37.89% YoY) and the FY2025 annual result came in at $150.2 million, up 1.53% from the prior year.
• Accumulated Expenses slipped to $27.0 million in Q1 2026 per AXSM's latest filing, from $150.2 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $150.2 million in Q4 2025 and troughed at $1.3 million in Q1 2023.
• A 5-year average of $28.1 million and a median of $13.6 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses tumbled 49.29% in 2022, then surged 2175.67% in 2024.
• Over 5 years, Accumulated Expenses stood at $4.7 million in 2022, then surged by 37.95% to $6.5 million in 2023, then soared by 2175.67% to $148.0 million in 2024, then grew by 1.53% to $150.2 million in 2025, then plunged by 82.01% to $27.0 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $27.0 million, $150.2 million, and $12.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.